APA (7th ed.) Citation

Kaufman, H. L., Andtbacka, R. H. I., Collichio, F. A., Wolf, M., Zhao, Z., Shilkrut, M., . . . Ross, M. (2017). Durable response rate as an endpoint in cancer immunotherapy: Insights from oncolytic virus clinical trials. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Kaufman, Howard L., Robert H. I. Andtbacka, Frances A. Collichio, Michael Wolf, Zhongyun Zhao, Mark Shilkrut, Igor Puzanov, and Merrick Ross. Durable Response Rate as an Endpoint in Cancer Immunotherapy: Insights from Oncolytic Virus Clinical Trials. BMJ Publishing Group, 2017.

MLA (9th ed.) Citation

Kaufman, Howard L., et al. Durable Response Rate as an Endpoint in Cancer Immunotherapy: Insights from Oncolytic Virus Clinical Trials. BMJ Publishing Group, 2017.